Trial Profile
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Upadacitinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ALINA
- Sponsors Chugai Pharmaceutical; Roche
- 18 Apr 2024 According to Genentech media release, based upon this trial the U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors = 4 cm or node positive), as detected by an FDA-approved test.
- 24 Oct 2023 Results from the prespecified interim analysis (At data cutoff 26 June 2023) assessing the efficacy and safety of adjuvant alectinib versus chemotherapy in patients with non-small cell lung cancer, presented at the 48th European Society for Medical Oncology Congress.
- 18 Oct 2023 Results published in the Genentech Media Release